World's Best Scientists 2026 revealed!
Garrett M. Frampton

Garrett M. Frampton

D-Index & Metrics

Medicine

D-Index
87
Citations
47481
World Ranking
13394
National Ranking
6811

Overview

Garrett M. Frampton is affiliated with Foundation Medicine in the United States. Their research contributions focus primarily on medicine, with significant work in biochemistry, genetics, and molecular biology. The scientist has a strong research presence in cancer research and oncology, with additional focus on pulmonary and respiratory medicine, molecular biology, and genetics.

Their main research topics include:

  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Genetic factors in colorectal cancer
  • BRCA gene mutations in cancer
  • Radiomics and Machine Learning in Medical Imaging
  • PARP inhibition in cancer therapy

Garrett M. Frampton has contributed to various notable publications, particularly in these venues:

  • Cancer Research
  • Journal of Clinical Oncology
  • JCO Precision Oncology
  • The Oncologist
  • Cancer Epidemiology Biomarkers & Prevention

Some of the recent papers to which they contributed include:

  • Mechanisms and therapeutic implications of hypermutation in gliomas (2020, Nature)
  • Clinical and analytical validation of FoundationOne®CDx, a comprehensive genomic profiling assay for solid tumors (2022, PLoS ONE)
  • Comprehensive Analysis of Genetic Ancestry and Its Molecular Correlates in Cancer (2020, Cancer Cell)
  • Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer (2021, Journal for ImmunoTherapy of Cancer)
  • Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response (2020, Cancer Discovery)

Frequent co-authors with whom Garrett M. Frampton has collaborated include:

  • Lee A. Albacker
  • Dean C. Pavlick
  • Alexa B. Schrock
  • Justin Y. Newberg
  • Ethan S. Sokol

Best Publications

  • Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial

    Jonathan E Rosenberg;Jean Hoffman-Censits;Tom Powles;Michiel S van der Heijden

  • Histone H3K27ac separates active from poised enhancers and predicts developmental state

    Menno P. Creyghton;Albert W. Cheng;G. Grant Welstead;Tristan G. Kooistra

  • Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

    Zachary R. Chalmers;Caitlin F. Connelly;David Fabrizio

  • Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

    Garrett M Frampton;Alex Fichtenholtz;Geoff A Otto;Kai Wang

  • Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.

    Aaron M. Goodman;Shumei Kato;Lyudmila Bazhenova;Sandip P. Patel

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Densely Interconnected Transcriptional Circuits Control Cell States in Human Hematopoiesis

    Noa Novershtern;Noa Novershtern;Noa Novershtern;Aravind Subramanian;Lee N. Lawton;Raymond H. Mak

  • Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

    Doron Lipson;Marzia Capelletti;Roman Yelensky;Geoff Otto

  • Foxp3 occupancy and regulation of key target genes during T-cell stimulation

    Alexander Marson;Karsten Kretschmer;Garrett M. Frampton;Elizabeth S. Jacobsen

  • Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities

    Ferdinandos Skoulidis;Lauren A. Byers;Lixia Diao;Vassiliki A. Papadimitrakopoulou

  • Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors

    Garrett M. Frampton;Siraj M. Ali;Mark Rosenzweig;Juliann Chmielecki

  • Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer

    Rinath Jeselsohn;Roman Yelensky;Gilles Buchwalter;Gilles Buchwalter;Garrett Frampton

  • Mechanisms and therapeutic implications of hypermutation in gliomas.

    Mehdi Touat;Mehdi Touat;Mehdi Touat;Yvonne Y. Li;Yvonne Y. Li;Adam N. Boynton;Adam N. Boynton;Liam F. Spurr;Liam F. Spurr

  • Enhancer decommissioning by LSD1 during embryonic stem cell differentiation

    Warren A. Whyte;Steve Bilodeau;David A. Orlando;Heather A. Hoke

  • Chromatin Structure and Gene Expression Programs of Human Embryonic and Induced Pluripotent Stem Cells

    Matthew G. Guenther;Garrett M. Frampton;Frank Soldner;Dirk Hockemeyer

  • Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

    Himisha Beltran;Roman Yelensky;Garrett M. Frampton;Kyung Park

  • Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

    Douglas B. Johnson;Garrett M. Frampton;Matthew J. Rioth;Erik Yusko

  • Derivation of Pre-X Inactivation Human Embryonic Stem Cells under Physiological Oxygen Concentrations

    Christopher J. Lengner;Alexander A. Gimelbrant;Jennifer A. Erwin;Jennifer A. Erwin;Albert Wu Cheng

  • Association of Patient Characteristics and Tumor Genomics With Clinical Outcomes Among Patients With Non-Small Cell Lung Cancer Using a Clinicogenomic Database

    Gaurav Singal;Gaurav Singal;Peter G. Miller;Vineeta Agarwala;Gerald Li

  • PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.

    Mark Yarchoan;Lee A. Albacker;Alexander C. Hopkins;Meagan Montesion

Frequent Co-Authors

Siraj M. Ali
Siraj M. Ali Foundation Medicine
Philip J. Stephens
Philip J. Stephens Foundation Medicine
Jeffrey S. Ross
Jeffrey S. Ross Foundation Medicine
Brian M. Alexander
Brian M. Alexander Foundation Medicine
Razelle Kurzrock
Razelle Kurzrock Medical College of Wisconsin
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Nir Peled
Nir Peled Hebrew University of Jerusalem
Shridar Ganesan
Shridar Ganesan Rutgers, The State University of New Jersey

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA often leads students to consider related healthcare degrees and alternative career pathways. Many accredited programs now offer flexible online options, letting you balance studies with work or other commitments. For nurses seeking to advance quickly, a 1 year dnp program online can be a fast track to leadership and clinical expertise roles without a lengthy time commitment.

If you’re starting your healthcare journey, a fast lpn program offers an accelerated path into nursing, providing essential clinical experience in as little as a year. Those with a master’s degree who want to specialize further can explore the shortest post master's pmhnp online programs, which focus on psychiatric and mental health nurse practitioner credentials.

For aspiring healthcare managers, a health care administration degree online is an affordable, flexible choice that prepares graduates for leadership in hospitals, clinics, or public health organizations. Each option brings unique benefits, helping you tailor your education to specialized interests and evolving healthcare needs.

Best Scientists Citing Garrett M. Frampton

Trending Scientists